Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways

Namodenoson, an A(3) adenosine receptor (A(3)AR) agonist, is currently being used in a phase III trial in advanced liver cancer. We examined the anti-growth effect of namodenoson on pancreatic carcinoma cells and investigated the molecular mechanism involved. BxPC-3 pancreatic carcinoma cells were c...

Descripción completa

Detalles Bibliográficos
Autores principales: Itzhak, Inbal, Bareket-Samish, Avital, Fishman, Pnina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669398/
https://www.ncbi.nlm.nih.gov/pubmed/38002266
http://dx.doi.org/10.3390/biom13111584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669398/
https://www.ncbi.nlm.nih.gov/pubmed/38002266
http://dx.doi.org/10.3390/biom13111584

Ejemplares similares